GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BIO-11006 overview
BIO-11006 is under development for the treatment of Osteosarcoma, Ewing Sarcoma. The drug candidate is administered as an aerosolized inhalational solution. The drug candidate is a crystalline, small soluble peptide with ten amino acids. It targets myristoylated alanine-rich C-kinase substrate (MARCKS) protein. It is derived from the…